The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1255
February 26, 2007
View Complete Issue         Table of Contents 2019 
Two New Drugs for Renal Cell Carcinoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two New Drugs for Renal Cell Carcinoma
February 26, 2007 (Issue: 1255)
Sunitinib (Sutent - Pfizer) and sorafenib (Nexavar - Bayer), two oral tyrosine kinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma (RCC). Sunitinib is also approved for use in patients with gastrointestinal...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Drugs for Renal Cell Carcinoma
Article code: 1255b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.